Allgens Medical

Allgens Medical Technology Co., Ltd. was established in 2004. It is a Sino-foreign joint venture of medical devices focusing on R&D, production and sales of tissue engineering materials, mainly involving new biodegradable materials. The company has been recognized as a high-tech enterprise in Beijing, a national high-tech enterprise, and was selected as an innovation leading enterprise in the Beijing Biomedical Industry Leap-over Development Project (G20 Project). The company has a 10,000-level clean production workshop, and has established a strict quality management system in accordance with the "Medical Device Manufacturing Quality Management Standard (GMP) Implantable Medical Device Implementation Rules" and YY/T 0287 requirements, and has passed the GMP audit certification of CFDA and international quality management system certification, ISO13485 and ISO9001.

Allgens is a national high-tech enterprise dedicated to the R&D, production and sales of high-end implantable medical devices for tissue regeneration and repair. Relying on the patented technology of Tsinghua University and more than ten years of independent research and development accumulation, a series of biomimetic mineralized collagen artificial bone repair products have been developed, covering four major categories of orthopedics, stomatology, plastic surgery, and neurosurgery, with more than 50 varieties . The company's products and technologies now have more than 50 Chinese patents and more than 10 overseas patents.

In May 2021, it successfully listed on SSE STAR Market (Stock code:688613). With its excellent R&D capabilities and expanding productivity, ALLGENS has created a miracle of the rapid development of domestic medical device companies in China.

Allgens's biomimetic mineralized collagen bone repair products have now obtained three China CFDA Class III medical device registration certificates in the fields of orthopedics, stomatology, and neurosurgery. as well as the US FDA medical device product registration certificates. The product has been used clinically for more than 200,000 cases in China and the United States, and the bone regeneration and repair effect is good.

Allgens has strong strength in the research and development of biomedical materials and medical device products, and has maintained long-term good scientific research and clinical cooperation with Tsinghua University, Beijing Jishuitan Hospital, Chinese People's Liberation Army General Hospital, Peking Union Medical College Hospital, Peking University People's Hospital, etc. The company has successively undertaken a number of major projects of the National 863 Plan, the National Science and Technology Support Plan, and the Beijing Science and Technology Plan Project.

Allgens's mineralized collagen artificial bone repair material product BONGOLD® , obtained the US FDA 510 (k) market access permit (K141725) in July 2015, and has been used in thousands of cases in the United States with good results.

Allgens's mineralized collagen artificial bone repair material products include “BONGOLD®”, SKUHEAL®”, OssaNova®”, and has obtained three CFDA Class III medical device product registration certificates, and has been clinically used in over a million cases to date, with good repair result.

ALLGENS'S MISSION: Deeply cultivate regenerative medicine to achieve a healthy and beautiful life.

ALLGENS'S CONCEPTS OF DEVELOPMENT: Bringing the gospel to thousands of patients and leading the health industry.

ALLGENS'S PURSUIT: To repair damaged bones, we continue to explore, to protect the health of patients, we never stop

BRAND ASSURANCE: The FIRST LISTED company in the field of bone graft material in China.